IMR Press / CEOG / Volume 36 / Issue 3 / pii/1630635714776-889891766

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
The effect of cetrorelix vs ganirelix on pregnancy outcome using minimal gonadotropin stimulation in women with elevated day 3 serum follicle stimulating hormone levels
Show Less
1 The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ (USA)
Clin. Exp. Obstet. Gynecol. 2009, 36(3), 148–149;
Published: 10 September 2009
Abstract

Purpose: To determine if the choice of gonadotropin releasing hormone antagonist influences subsequent pregnancy rates in women with diminished egg reserve. Method: Retrospective determination of pregnancy rates following embryo transfer in women with day 3 FSH >12 mIU/ml using lower dose gonadotropin stimulation regimen. Results: Though no significant differences were found there was a trend for lower pregnancy rates with ganirelix vs cetrorelix. Conclusions: The trend for lower pregnancy rates with ganirelix vs cetrorelix seen in women with diminished egg reserve is consistent with the findings of a study performed in women with normal egg reserve using a normal gonadotropin stimulation regimen. It is not clear if the adverse effect is on the endometrium or the embryo.
Keywords
Decreased egg reserve
Ganirelix
Cetrorelix
IVF-ET
Share
Back to top